| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology, and Genetics |
B Activity
1 Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Lerner School of Medicine, Cleveland, Ohio and 2 Department of Pathology, Comprehensive Cancer Center, and National Foundation for Cancer Research Center for Metastasis Research, University of Alabama at Birmingham, Birmingham, Alabama
Requests for reprints: Graham Casey, Department of Cancer Biology, ND50, Lerner Research Institute, Cleveland Clinic Lerner School of Medicine, 9500 Euclid Avenue, Cleveland, OH 44195. Phone: 216-445-9754; Fax: 216-445-0610; E-mail: caseyg{at}ccf.org.
Breast cancer metastasis suppressor 1 (BRMS1) functions as a metastasis suppressor gene in breast cancer and melanoma cell lines, but the mechanism of BRMS1 suppression remains unclear. We determined that BRMS1 expression was inversely correlated with that of urokinase-type plasminogen activator (uPA), a prometastatic gene that is regulated at least in part by nuclear factor-
B (NF-
B). To further investigate the role of NF-
B in BRMS1-regulated gene expression, we examined NF-
B binding activity and found an inverse correlation between BRMS1 expression and NF-
B binding activity in MDA-MB-231 breast cancer and C8161.9 melanoma cells stably expressing BRMS1. In contrast, BRMS1 expression had no effect on activation of the activator protein-1 transcription factor. Further, we showed that suppression of both constitutive and tumor necrosis factor-
induced NF-
B activation by BRMS1 may be due to inhibition of I
B
phosphorylation and degradation. To examine the relationship between BRMS1 and uPA expression in primary breast tumors, we screened a breast cancer dot blot array of normalized cDNA from 50 breast tumors and corresponding normal breast tissues. There was a significant reduction in BRMS1 mRNA expression in breast tumors compared with matched normal breast tissues (paired t test, P < 0.0001) and a general inverse correlation with uPA gene expression (P < 0.01). These results suggest that at least one of the underlying mechanisms of BRMS1-dependent suppression of tumor metastasis includes inhibition of NF-
B activity and subsequent suppression of uPA expression in breast cancer and melanoma cells.
This article has been cited by other articles:
![]() |
D. R. Hurst, Y. Xie, K. S. Vaidya, A. Mehta, B. P. Moore, M. A. Accavitti-Loper, R. S. Samant, R. Saxena, A. C. Silveira, and D. R. Welch Alterations of BRMS1-ARID4A Interaction Modify Gene Expression but Still Suppress Metastasis in Human Breast Cancer Cells J. Biol. Chem., March 21, 2008; 283(12): 7438 - 7444. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Phadke, K. S. Vaidya, K. T. Nash, D. R. Hurst, and D. R. Welch BRMS1 Suppresses Breast Cancer Experimental Metastasis to Multiple Organs by Inhibiting Several Steps of the Metastatic Process Am. J. Pathol., March 1, 2008; 172(3): 809 - 817. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liu, P. W. Smith, and D. R. Jones Breast Cancer Metastasis Suppressor 1 Functions as a Corepressor by Enhancing Histone Deacetylase 1-Mediated Deacetylation of RelA/p65 and Promoting Apoptosis Mol. Cell. Biol., December 1, 2006; 26(23): 8683 - 8696. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Hicks, B. J. Yoder, S. Short, S. Tarr, N. Prescott, J. P. Crowe, A. E. Dawson, G. T. Budd, S. Sizemore, M. Cicek, et al. Loss of Breast Cancer Metastasis Suppressor 1 Protein Expression Predicts Reduced Disease-Free Survival in Subsets of Breast Cancer Patients. Clin. Cancer Res., November 15, 2006; 12(22): 6702 - 6708. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Zhang, H. Yamashita, T. Toyama, Y. Yamamoto, T. Kawasoe, and H. Iwase Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer. Clin. Cancer Res., November 1, 2006; 12(21): 6410 - 6414. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Albini, F. Tosetti, R. Benelli, and D. M. Noonan Tumor Inflammatory Angiogenesis and Its Chemoprevention Cancer Res., December 1, 2005; 65(23): 10637 - 10641. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |